Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Venetoclax and BEAM followed by ASCT for R/R NHL

Joseph Maakaron • 9 Feb 2021
TCT 2021
Lymphoma Non-Hodgkin Lymphoma Venetoclax

Joseph Maakaron, MD, University of Minnesota, Minneapolis, MN, discusses the results of a Phase I dose-escalation study investigating venetoclax plus BEAM followed by autologous stem cell transplant (ASCT) for chemoresistant or high-risk relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). In this trial, venetoclax and BEAM demonstrated promising results as a safe and well-tolerated approach in a typical, elderly population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals